
WE CLAIM:

1. Use of Compound 1 having the structure  in the manufacture of a medicament for the treatment of heart failure, wherein a therapeutically effective amount of Compound 1 is to be administered to a patient in need thereof, wherein the heart failure is selected from the group consisting of congestive heart failure, systolic heart failure, diastolic heart failure, heart failure with reduced ejection fraction (HF_REF), heart failure with preserved ejection fraction (HF_PEF), acute heart failure, chronic heart failure of ischemic and non-ischemic origin.

2. The use of claim 1, wherein the heart failure is heart failure with reduced ejection fraction (HF_rEF).

3. The use of claim 2, wherein the HF_rEF results from myocardial infarction.

4. The use of claim 3, wherein Compound 1 is to be administered after the diagnosis of myocardial infarction in the patient.

5. The use of claim 4, wherein Compound 1 is to be administered 24 to 48 hours after the diagnosis of myocardial infarction in the patient.

6. The use of claim 4, wherein Compound 1is to be administered to the patient between 1 and 7 days after the diagnosis of myocardial infarction in the patient.

7. The use of claim 1, wherein Compound 1is to be administered orally.

8. The use of claim 1, wherein administration of Compound 1 improves left ventricle function.

9. The use of claim 1, wherein administration of Compound 1 prevents progression of myocardial wall thinning.

10. The use of claim 1, wherein administration of Compound 1 inhibits cardiomyocyte cell death.

11. The use of claim 1, wherein administration of Compound 1 reduces infarct size.

12. The use of claim 1, wherein administration of Compound 1 reduces hypertrophy in the heart tissue.

13. The use of claim 1, wherein Compound 1 is to be administered daily.

14. The use of claim 1, wherein Compound 1 is to be administered for at least one, two, three, four, five, or six weeks.

15. The use of claim 1, wherein the heart failure is HF_PEF.

16. The use of claim 15, wherein Compound 1 is to be administered for at least one, two, three, four, five, or six weeks.

17. The use of claim 15 wherein administration of Compound 1 improves myocardial wound healing.

18. The use of claim 15 wherein administration of Compound 1 reduces ventricular fibrosis.

19. The use of claim 1, wherein the status of the condition of the patient's heart is assessed between each dose and the dose and/or timing of administration is adjusted in accord with the condition of the heart.

20. The use of claim 1, wherein the use comprises treatment of heart failure with a second agent.

21. The use of claim 20, wherein the second agent is selected from a diuretic, loop diuretic, a potassium sparing agent, a vasodilator, an ACE inhibitor, an angiotensin receptor blocker, an angiotensin II inhibitor, an aldosterone inhibitor, a positive inotrophic agent, a phosphodiesterase inhibitor, a beta-adrenergic receptor inhibitor, a calcium channel blocker, an alpha blocker, a central alpha blocker, a sodium-glucose co-transporter 2 inhibitor, a nitrate, a statin, a cardiac glycoside, digoxin, nitrates, chlorthalidone, amlodipine, lisinopril, and doxazosin.

22. Use of Compound 1 in manufacture of a medicament for the treatment of heart failure.

23. The use of claim 22, wherein said heart failure is HF_rEF or HF_pEF.